- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Echogenicity.
Displaying page 1 of 1.
| EudraCT Number: 2017-005050-11 | Sponsor Protocol Number: SeMMIviD | Start Date*: 2019-03-08 | |||||||||||
| Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI | |||||||||||||
| Full Title: Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial | |||||||||||||
| Medical condition: Graves' disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017245-64 | Sponsor Protocol Number: OG09/9146 | Start Date*: 2010-09-07 |
| Sponsor Name:Leeds Teaching Hospitals NHS Trust | ||
| Full Title: The effect of metformin co-treatment in hormone-replacement frozen embryo replacement cycles in women with polycystic ovary syndrome. | ||
| Medical condition: Polycystic Ovary Syndrome | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2018-002929-36 | Sponsor Protocol Number: TBFP2018 | Start Date*: 2019-04-30 |
| Sponsor Name:Dra. Virginia Raquel Céspedes Nava | ||
| Full Title: COMPARATIVE STUDY OF THE EFFICACY OF THE TREATMENT OF PLANTAR FASCITIS WITH INFILTRATION OF CORTICOIDS VS BOTULINIC TOXIN. ECOGRAPHIC FINDINGS | ||
| Medical condition: Plantar fasciitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-003557-15 | Sponsor Protocol Number: HMB-ICU | Start Date*: 2018-08-31 | |||||||||||
| Sponsor Name:Guy's and St Thomas NHS Foundation Trust | |||||||||||||
| Full Title: A Study to Investigate the Effect of β-Hydroxy-β-Methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness. | |||||||||||||
| Medical condition: Critical illness | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-004145-41 | Sponsor Protocol Number: 8638 | Start Date*: 2013-05-22 | |||||||||||
| Sponsor Name:UH Montpellier | |||||||||||||
| Full Title: Efficacy and safety of acebutolol versus propranolol in the proliferative phase of infantile hemangiomas | |||||||||||||
| Medical condition: Infant 0 to 6 months Non-serious hemangioma | |||||||||||||
|
|||||||||||||
| Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-001053-44 | Sponsor Protocol Number: Carotis-Rivaroxaban_CEUS_001 | Start Date*: 2020-09-30 | |||||||||||
| Sponsor Name:Rigshospitalet, Department of Vascular Surgery | |||||||||||||
| Full Title: Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS) | |||||||||||||
| Medical condition: Patients with - Stable peripheral artery disease and - Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-017010-68 | Sponsor Protocol Number: 1235.34 | Start Date*: 2010-07-21 | |||||||||||
| Sponsor Name:Universitätsmedizin der Johannes Gutenberg-Universität Mainz | |||||||||||||
| Full Title: A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure | |||||||||||||
| Medical condition: Male and female, treated and treatment-naive patients with uncontrolled hypertension (defined as 20/10 mmHg above target BP of <140/90 mmHg [<130/80 mmHg for renally impaired and/ or diabetics pa... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-018289-21 | Sponsor Protocol Number: EndoIGA2010 | Start Date*: 2010-02-25 | |||||||||||||||||||||||||||||||
| Sponsor Name:Insitute of Endocrinology | |||||||||||||||||||||||||||||||||
| Full Title: Clinical, laboratory and ultrasound markers for the prediction of the response on the pulse-dose treatment by intravenous glucocorticoids in patients with endocrine orbitopathy | |||||||||||||||||||||||||||||||||
| Medical condition: active severe endocrine orbitopathy | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: CZ (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-013342-92 | Sponsor Protocol Number: DSE-OLM-01-09 | Start Date*: 2010-06-08 | |||||||||||
| Sponsor Name:DAIICHI SANKYO EUROPE GmbH | |||||||||||||
| Full Title: EFFECTS OF ANGIOTENSIN-RECEPTOR BLOCKADE WITH OLMESARTAN ON CAROTID ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION: THE CONFIRMATORY OLMESARTAN PLAQUE REGRESSION STUDY (CONFIRM) | |||||||||||||
| Medical condition: Essential hypertension in subjects with documented carotid atherosclerosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Prematurely Ended) IT (Prematurely Ended) CZ (Completed) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-000499-83 | Sponsor Protocol Number: 1386.4 | Start Date*: 2017-05-04 | |||||||||||
| Sponsor Name:Boehringer Ingelheim bv | |||||||||||||
| Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo controlled phase II a study to investigate safety, tolerability, pharmacodynamics, and harmacokinetics of different doses of orall... | |||||||||||||
| Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) BE (Completed) DE (Completed) IE (Completed) GB (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001107-38 | Sponsor Protocol Number: SESCHI.26371 | Start Date*: 2008-05-26 | |||||||||||
| Sponsor Name:Cefak KG | |||||||||||||
| Full Title: Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cef... | |||||||||||||
| Medical condition: Autoimmune thyroiditis (Hashimoto-thyroiditis) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.